# High-Volume Hemodiafiltration

## Executive Summary

HVHDF combines diffusive and convective clearance to achieve **23–37% mortality reductions** compared to conventional hemodialysis when convection volumes exceed 23 liters per session. Evidence base: five major RCTs (\>4,000 patients), meta-analyses, and real-world data from \>85,000 patients. FDA-cleared 5008X system available in the US since February 2024.

## Clinical Evidence Foundation

### Landmark Randomized Controlled Trials

| Study | N (HD/HDF) | Mean Conv. Vol (L) | Primary Outcome | Key Finding |
|----|----|----|----|----|
| **CONTRAST** (2012) | 356/358 | 19.8 | All-cause mortality | No overall difference; \>21.9 L: HR 0.62 (38% reduction) |
| **Turkish OL-HDF** (2013) | 391/391 | 19.5 | Mortality + CV events | \>17.4 L: HR 0.71 (29% reduction) |
| **ESHOL** (2013) | 450/456 | 23.9 | All-cause mortality | **30% reduction** (HR 0.70, p=0.01); \>25 L: 45% reduction |
| **FRENCHIE** | 191/190 | 21.0 | Intradialytic tolerance | Better tolerance; no mortality difference |
| **CONVINCE** (2023) | 683/677 | 25.5 | All-cause mortality | **23% reduction** (HR 0.77, p\<0.001); cognitive preservation |

### IPD Meta-Analysis (Vernooij et al., 2024)

Combining all five RCTs, patients achieving convection volumes \>23 L/session experienced:

- **37% reduction** in all-cause mortality
- **42% reduction** in cardiovascular mortality
- **49% reduction** in infection-related mortality

### Real-World Evidence

85,117 patients across 23 countries: **22% mortality reduction** for HDF vs. high-flux HD, increasing to 30% at high-volume targets. Brazilian cohort (8,391 patients): 27% reduction, particularly pronounced in patients \<65 years.

## Mechanistic Understanding

### Enhanced Solute Clearance

- Beta-2 microglobulin clearance: **73 mL/min** (nearly double high-flux HD)
- Documented reductions in CRP, IL-6, and TNF-alpha
- Reduced long-term dialysis-related amyloidosis

### Hemodynamic Stability

- **50% reduction** in symptomatic intradialytic hypotension
- Gibbs-Donnan effect promotes sodium retention and plasma refilling
- Cooling effect from substitution fluid infusion
- Improved endothelial function and reduced arterial stiffness
- Slower progression of vascular calcification

### Infection Risk Reduction

31–49% reduction in infection-related mortality. Enhanced removal of immunosuppressive middle molecules (GIPs, free immunoglobulin light chains) restores immune competence. Improved vaccine response including higher antibody titers after influenza and SARS-CoV-2 vaccination.

## Prescription Calculations

### Core Formula

**Convection Volume (L) = \[Qb (mL/min) × Time (min) × FF (%)\] / 1000 + Net UF (L)**

### Example 1: Standard HVHDF Patient (75 kg, AVF)

Qb = 370 mL/min \| Time = 240 min \| FF = 30% \| Net UF = 2.5 L\
\
Blood volume = 370 × 240 / 1000 = **88.8 L**\
Substitution = 88.8 × 0.30 = **26.6 L**\
Convective vol = 26.6 + 2.5 = **29.1 L** (exceeds 23 L target)\
Qd = 370 × 1.2 = **444 mL/min**\
Effective FF = 29.1 / 88.8 = **32.8%**

### Example 2: Catheter-Limited Patient

Qb = 300 mL/min \| Time = 240 min \| FF = 30% \| Net UF = 2.0 L\
\
Blood volume = 300 × 240 / 1000 = **72.0 L**\
Substitution = 72.0 × 0.30 = **21.6 L**\
Convective vol = 21.6 + 2.0 = **23.6 L** (borderline)\
\
**Optimization A:** Increase FF to 33% → 23.8 + 2.0 = **25.8 L**\
**Optimization B:** Extend to 270 min → 81 × 0.30 = 24.3 + 2.0 = **26.3 L**

### Variable Selection Guide

| Variable | Type | Range | Decision Points |
|----|----|----|----|
| Blood Flow (Qb) | Selected | 330–400 mL/min | AVF/AVG: 350–400; CVC: 300–330 |
| Treatment Time | Selected | 210–270 min | Standard: 240; extend for CVC patients |
| Filtration Fraction | Selected | 25–35% | Standard: 30%; max safe: 35% |
| Qd:Qb Ratio | Selected | 1.0–1.5 | Start at 1.2; adjust based on Kt/V |
| **Convective Volume** | Calculated | **\>23 L target** | Substitution + net UF |
| Kt/V | Calculated | \>1.4 | Based on total (diffusive + convective) clearance |

## Progressive Implementation Protocol

| Parameter              | Week 1  | Week 2  | Week 3  | Week 4  | Week 5  |
|------------------------|---------|---------|---------|---------|---------|
| Frequency              | ≥2      | ≥3      | ≥3      | ≥3      | ≥3      |
| Time (min)             | 120–180 | ≤180    | ≤240    | ≤240    | ≥240    |
| Qb (mL/min)            | ≤150    | ≤200    | ≤250    | ≤300    | ≥340    |
| Post-dilution Qsub (L) | 0       | ≤5      | ≤10     | ≤15     | ≥21     |
| Dialysate Na (mEq/L)   | 140–143 | 140–142 | 140–141 | 139–140 | 138–140 |
| spKt/V Target          | —       | —       | —       | ≥1.4    | ≥1.4    |

### Quality Assurance

Monthly average target: \>25 L convection volume\
Acceptable range: ±10% of target\
Investigation trigger: \<23 L in \>20% of sessions

### Troubleshooting: Suboptimal Convection Volumes

Current: Qb 320 × 240 × 0.28 / 1000 = 21.5 L (inadequate)\
\
Option A: Increase Qb to 350 → 23.5 L (+2.0 L)\
Option B: Extend to 270 min → 24.2 L (+2.7 L)\
Option C: Increase FF to 32% → 24.6 L (+3.1 L; monitor TMP)

## Patient Selection

### Optimal Candidates

- Robust vascular access capable of high blood flows
- Active transplant candidates (cardiovascular protection)
- Patients with recurrent infections
- Hemodynamic instability or heart failure
- Dialysis-related amyloidosis or elevated beta-2 microglobulin

### Infrastructure Requirements

- Ultrapure water: ANSI/AAMI/ISO 23500-2019 (\<0.1 CFU/mL, \<0.03 EU/mL endotoxin)
- Two-stage ultrafiltration achieving sterility assurance level of 6 magnitudes
- Comprehensive staff training on optimization and troubleshooting

## Medication Management

Dosing Adjustments Required

HVHDF's enhanced convective clearance increases removal of middle-molecular-weight drugs. **Vancomycin:** 1 g initially, then 500 mg at each of the next 3 sessions. Piperacillin/tazobactam and ceftazidime require post-dialysis dosing as for GFR 10–20 mL/min.

- Small-molecule drugs cleared by diffusion: minimal changes
- Highly protein-bound drugs: unaffected regardless of modality
- MW 500–5,000 Da with low protein binding: may need TDM

## United States Implementation Status

- **FDA clearance:** 5008X system, February 2024
- **First US treatment:** January 24, 2025 (Fresenius Kidney Care, Wellesley, MA) — 25.5 L substitution over 215 minutes
- Global experience: \>26,000 patients in FMC European/MENA clinics with mean convection volume of 27.4 L/session

### Cost-Effectiveness

CONVINCE economic evaluation: ICER of €27,068–36,751/QALY over lifetime horizon, well below €50,000 threshold. Optimized HVHDF (Qd:Qb = 1.2 vs. 1.5) reduces dialysis fluid consumption by 26% (~26 L/session savings).

Clinical Pearl

The ability to reduce mortality by **nearly 40% when delivered optimally** places HVHDF among the most impactful interventions in nephrology. The challenge is no longer proving efficacy but ensuring equitable access and maintaining quality standards.

## Key References

1.  Vernooij RWM, Hockham C, Strippoli G, et al. Haemodiafiltration versus haemodialysis for kidney failure: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2024;. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39489903/)
2.  CONVINCE Study Group. HVHDF vs. high-flux HD: a multinational RCT. *N Engl J Med*. 2023;389(8):700-709. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37326323/)
3.  Maduell F, et al. High-efficiency postdilution OL-HDF reduces mortality (ESHOL). *J Am Soc Nephrol*. 2013;24(3):487-497. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23411788/)
4.  Grooteman MP, et al. OL-HDF and HD: CONTRAST trial. *J Am Soc Nephrol*. 2012;23(6):1087-1096. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22539829/)
5.  Ok E, et al. Mortality and cardiovascular events in OL-HDF: Turkish study. *Nephrol Dial Transplant*. 2013;28(1):192-202. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23229932/)

## Related Mastery Modules

### Also on this topic

The same subject at other levels of depth.

- **Student handout:** [High-Volume Hemodiafiltration (HVHDF): Student Handout](https://urinenephrology.org/student-resources/dialysis/hvhdf-student-handout.html)


---

[Website version](https://urinenephrology.org/mastery/dialysis-advanced/hvhdf.html) · Markdown synchronized October 3, 2026.